Please enable JavaScript in your browser. 

Important Announcement


DrugPortal is moving to PubChem in December 2022.
Please see the NLM Technical Bulletin article for more information.

Skip to main content
Drug Information Portal National Library of Medicine
       Home    Substance
1 result for Name/Synonym equals OSIMERTINIB 
Drug Name: Osimertinib [USAN] View Structure
Description: An EGFR tyrosine kinase inhibitor.

NCI: EGFR inhibitor AZD9291. An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, AZD9291 selectively and covalently binds to and inhibits the activity of the mutant forms of EGFR, including the T790M EGFR mutant form, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase overexpressed or mutated in many types of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As AZD9291 inhibits T790M, a secondarily acquired resistance mutation, this agent may have therapeutic benefits in tumors with T790M-mediated resistance. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.(NCI Thesaurus) 

Site Map, Contact Us, Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services
Freedom of Information Act
HHS Vulnerability Disclosure
Drug Information Portal Mobile Site
Last updated: Nov 2022